Summary for peptidase M20.001: glutamate carboxypeptidase

Summary Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma


MEROPS Nameglutamate carboxypeptidase
Other namescarboxypeptidase G, carboxypeptidase G1, carboxypeptidase G2, CPG2, glucarpidase, voraxaze
Domain architecture
MEROPS Classification
Classification Clan MH >> Subclan (none) >> Family M20 >> Subfamily A >> M20.001
Holotypeglutamate carboxypeptidase (Pseudomonas sp.), Uniprot accession P06621 (peptidase unit: 23-415), MERNUM MER0001266
History Identifier created: Handbook of Proteolytic Enzymes (1998) Academic Press, London.
Catalytic typeMetallo
PeplistIncluded in the Peplist with identifier PL00229
NC-IUBMBSubclass 3.4 (Peptidases) >> Sub-subclass 3.4.17 (Metallocarboxypeptidases) >> Peptidase
EnzymologyBRENDA database
PhysiologyPresumably contributes to to the bacterial nutrition.
Pharmaceutical relevanceRescue agent during high-dose methotrexate therapy, but it is notable that the enzyme also hydrolyses leucovorin, which is is also administered to antagonise unexpected adverse effects of methotrexate, so it is suggested that the two agents not be administered together (Hempel et al., 2005). Glutamate carboxypeptidase has been the subject of considerable research in experimental prodrug strategies for cancer therapy including "antibody-directed enzyme prodrug therapy" (ADEPT) (Bhatia et al., 2000; Burke, 2000; Friedlos et al., 2002).